Overview

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Status:
Enrolling by invitation

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Lacosamide